BACE1 and Alzheimer disease: BACE1 is an important target in the treatment of Alzheimer’s disease (AD), and it catalyzes the rate-limiting step in amyloid-β (Aβ) production [96,97], which exacerbates neuroinflammation, and promotes vascular and parenchymal damage.